A Phase II, Open-Label, Multicenter Study to Evaluate the Effect of Tumor-Based HER2 Activation on the Efficacy of rhuMAb 2C4 (Pertuzumab) in Subjects With Recurrent Non-Small Cell Lung Cancer.

Trial Profile

A Phase II, Open-Label, Multicenter Study to Evaluate the Effect of Tumor-Based HER2 Activation on the Efficacy of rhuMAb 2C4 (Pertuzumab) in Subjects With Recurrent Non-Small Cell Lung Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Jun 2015

At a glance

  • Drugs Pertuzumab (Primary)
  • Indications Non-small cell lung cancer
  • Focus Biomarker; Therapeutic Use
  • Sponsors Genentech
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 24 Aug 2008 Actual end date (Dec 2004) added as reported by ClinicalTrials.gov.
    • 24 Sep 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top